mPEG2000-DMPE
mPEG2000-DMPE is a pegylated lipid with a methyl group at the opposite end of the PEG chain, and can be used for the preparation of lipid nanoparticles or liposomes for targeted drug delivery applications. mPEG2000-DMPE is applicable for siRNA-related application studies targeting macrophages and dendritic cells.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1254157-61-3
- Molecular Weight:2000 (Average)
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
Lipid nanoparticles containing mPEG2000-DMPE (6.25-50 nmol/L; 2 days) deliver CD45 siRNA to murine inflammatory peritoneal macrophages to induce dose-dependent knock-down of CD45 mRNA (up to 91% suppression) and protein (up to 56% suppression) in vitro[1].
Lipid nanoparticles containing mPEG2000-DMPE (50 nmol/L; 3 days) deliver CD45 siRNA to human monocyte-derived macrophages to induce 70% suppression of CD45 mRNA and 20% suppression of CD45 protein in vitro[1].
Lipid nanoparticles containing mPEG2000-DMPE (50 nmol/L; 3 days) deliver CD45 siRNA to human monocyte-derived dendritic cells to induce 50% suppression of CD45 mRNA and 30% suppression of CD45 protein in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 1254157-61-3
-
Molecular Weight 2000 (Average)
-
SMILES
[H][C@@](COP(O)(OCCNC(OCCOCC)=O)=O)(OC(CCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCC)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RNA interference technology
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing gene transcription or activating RNA degradation. This mechanism was discovered in plants in 1998 by Andrew Fire and Craig Mello. Today, this phenomenon can be observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals.
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)